| Literature DB >> 26136849 |
Jeffrey L Tapley1, Gerald McGwin2, Ambika P Ashraf3, Paul A MacLennan4, Koula Callahan1, Karen Searcey1, C Douglas Witherspoon1, Jinan Saaddine5, Cynthia Owsley1.
Abstract
BACKGROUND: We examined the feasibility and efficacy of using a non-mydriatic camera to screen for diabetic retinopathy (DR) among youth with type 1 or type 2 diabetes seen in a pediatric endocrinology clinic serving Alabama, the state that has the highest diabetes rate in the United States.Entities:
Keywords: Diabetes complications; Diabetes mellitus; Diabetic retinopathy; Pediatrics; Visual acuity
Year: 2015 PMID: 26136849 PMCID: PMC4487844 DOI: 10.1186/s13098-015-0054-z
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Diabetic retinopathy (DR) grading based on the National Health Service Grading Classification System [17] with follow-up recommendations adapted from the American Academy of Ophthalmology [18]
| Grade | Description | Recommendation |
|---|---|---|
| R0 | No diabetic retinopathy | Re-evaluate in twelve months with either eye care provider or photographic screening |
| R1 | Background DR | Refer to eye care provider |
| R2 | Pre-proliferative DR | Refer to ophthalmologist promptly |
| R3 | Proliferative DR | Refer to ophthalmologist promptly |
| M | Maculopathy | Refer to ophthalmologist promptly |
| P | Photocoagulation | Refer to eye care provider |
| U | Unclassifiable/Ungradable | Refer to eye care provider |
Demographic, clinical, and laboratory characteristics of participants by recency of dilated eye examination
| Total ( | Eye exam ≤ 12 months ( | Eye exam > 12 months ( | Never ( |
| |
|---|---|---|---|---|---|
| Demographics | |||||
| Age, years, mean (standard deviation, SD) | 14.1 (2.69) | 14.1 (2.58) | 14.9 (2.7) | 12.8 (2.8) | 0.142 |
| Minimum - maximum | 8.0-18.9 | 8.0-18.9 | 9.4-18.9 | 8.3-18.4 | |
| Gender, N (%) | |||||
| Male | 101 (42.8) | 68 (43.6) | 22 (46.8) | 11 (33.3) | 0.459 |
| Female | 135 (57.2) | 88 (56.4) | 25 (53.2) | 22 (66.7) | |
| Race, N (%) | |||||
| White, non-Hispanic origin | 158 (67.0) | 109 (69.9) | 25 (59.6) | 21 (63.6) | 0.225 |
| African American | 70 (29.7) | 43 (27.6) | 17 (36.2) | 10 (30.3) | |
| Hispanic | 5 (2.1) | 3 (1.9) | 0 (0) | 2 (6.1) | |
| Native American | 2 (0.9) | 1 (0.6) | 1 (2.1) | 0 (0) | |
| Asian | 1 (0.4) | 0 (0) | 1 (2.1) | 0 (0) | |
| Clinical characteristics | |||||
| Type, n (%) | 0.824 | ||||
| Type 1 | 202 (85.6) | 135 (86.6) | 39 (83.0) | 28 (84.8) | |
| Type 2 | 34 (14.4) | 21 (13.5) | 8 (17.0) | 5 (16.0) | |
| Age at diabetes diagnosis, years, mean (SD) | 8.6 (3.9) | 8.2 (4.0) | 9.6 (4.0) | 9.2 (3.5) | 0.053 |
| Duration of diabetes diagnosis, years, mean (SD) | 5.5 (3.5) | 5.9 (3.4) | 5.4 (4.0) | 3.6 (2.5) | 0.001 |
| Laboratory characteristics | |||||
| HbA1c high for agea, n (%) | 169 (71.6) | 115 (73.7) | 32 (68.1) | 22 (66.7) | 0.599 |
| Cholesterolb, n (%) | |||||
| >75th percentile | 86 (34.4) | 51 (32.7) | 26 (55.3) | 9 (27.3) | 0.009 |
| LDLb, n (%) | |||||
| >75th percentile | 53 (22.5) | 33 (21.2) | 16 (34.0) | 4 (12.1) | 0.055 |
| HDLb, n (%) | |||||
| >75th percentile | 191 (80.9) | 122 (78.2) | 44 (93.6) | 25 (75.8) | 0.046 |
| Triglyceridesb, n (%) | |||||
| >75th percentile | 133 (56.4) | 85 (54.5) | 33 (70.2) | 15 (45.5) | 0.064 |
| Urine Albuminc n (%) | 0.963 | ||||
| Normal (<30 mg/L) | 213 (90.3) | 141 (90.4) | 42 (89.4) | 30 (90.9) | |
| Microalbuminuria (30–299 mg/L) | 22 (9.3) | 14 ( 9.0) | 5 (10.6) | 3 (9.1) | |
| Macroalbuminuria (≥300 mg/L) | 1 (0.4) | 1 (0.6) | 0 (0) | 0 (0) | |
aHbA1c is high if ≥ 8.5 % (69 mmol/mol) for < 6 years of age; ≥ 8.0 % (64 mmol/mol) for 6 – 12 years of age; ≥ 7.5 % (58 mmol/mol) for 13 – 19 years of age [2]
bPercentile categories are based from Gender and Age specific norms [19]
cUrine albumin was reported in mg/L; normal was < 30 mg/L, microalbuminuria was defined as ≥ 30 and < 300 mg/L, and macroalbuminuria was defined as ≥ 300 mg/L [20]
Descriptive characteristics of participants with diabetic eye disease
| Finding | Total ( |
|---|---|
| Total diabetic eye disease (including DR and maculopathy) | 9 (3.9) |
| Background DR | 7 (3.0) |
| Pre-proliferative DR | 0 (0) |
| Proliferative DR | 2 (0.9) |
| Maculopathy | 1 (0.4) |
| Other lesions | 10 (4.3) |
aFour subjects were unclassifiable/ungradable for both eyes
Visual acuity among study participants
| Visual acuity | Total sample ( | Omitting those who had glasses but did not bring them to appointment ( |
|---|---|---|
| Better eye acuity score | ||
| 20/20 | 96 (41.6) | 88 (49.7) |
| 20/30 | 90 (39.0) | 73 (41.2) |
| 20/40 | 29 (12.6) | 10 (5.7) |
| 20/50 | 13 (5.6) | 5 (2.8) |
| 20/70 | 3 (1.3) | 1 (0.6) |
| Worse eye acuity score | ||
| 20/20 | 56 (24.2) | 52 (29.4) |
| 20/30 | 92 (39.8) | 81 (45.8) |
| 20/40 | 38 (16.5) | 26 (14.7) |
| 20/50 | 26 (11.3) | 10 (5.7) |
| 20/70 | 11 (4.8) | 5 (2.8) |
| 20/100 | 8 (3.5) | 3 (1.7) |
aFive participants were unable to perform visual acuity test